First Page | Document Content | |
---|---|---|
![]() Date: 2015-01-14 05:46:19Pancreas disorders Anilides Ivacaftor Phenols Quinolones Cystic fibrosis Vertex Pharmaceuticals Epithelial sodium channel Sweat test Biology Health Medicine | Add to Reading List |
![]() | OPEN SUBJECT AREAS: FLUORESCENCE IMAGING DRUG DEVELOPMENT HIGH-THROUGHPUT SCREENINGDocID: 1pyUW - View Document |
![]() | Steven R. Boas, MD The Cystic Fibrosis Institute™ CEO and Founder Lois NelsonDocID: 19N8q - View Document |
![]() | Spyryx Biosciences Secures $18 Million in Series A Financing Funding to Develop Novel Therapeutics for Respiratory Diseases Venture Syndicate has Strong Respiratory ExpertiseDocID: 19HrV - View Document |
![]() | Clinical Commissioning Policy: Ivacaftor for Cystic Fibrosis (G551D mutation) Reference: NHS England A01/P/a 1DocID: 12swh - View Document |
![]() | Media Release 26 October 2014 Cystic fibrosis community breathes easy on news of Government subsidyDocID: ZcdY - View Document |